Should I Buy NSPR? NSPR 2026 Analysis

Should You Buy InspireMD Inc (NSPR) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.710

1 Day change

-3.79%

52 Week Range

2.930

Analysis Updated At

2026/06/19

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

InspireMD Inc (NSPR) is not a good buy for a beginner investor with a long-term strategy at this time. The stock is facing technical weakness, lacks strong positive catalysts, and has no significant trading signals to support an immediate entry point.

Technical Analysis

The stock shows bearish technical indicators. The MACD is below 0 and negatively contracting, RSI is neutral at 28.452, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.701, with resistance at 0.8.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

Analysts maintain a positive long-term view on the company's micromesh carotid stent technology despite recent setbacks. The company has shown strength in both U.S. and international markets during its Q1 performance.

Neutral/Negative Catalysts

The voluntary recall of the CGuard Prime 135 cm delivery system has delayed the U.S. launch and led to a reduction in 2026 revenue guidance. The stock has no recent news or significant trading trends, and technical indicators suggest bearish sentiment.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts have lowered price targets (Piper Sandler to $3 from $4, Lake Street to $4 from $5) but maintain positive ratings. The recall issue is seen as manageable, but it has impacted revenue guidance and investor sentiment.

1 Analyst Rating

Wall Street analysts forecast NSPR stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.738

Low

Averages

High

Current: 0.738

Low

Averages

High

Piper Sandler

Adam Maeder

Overweight

downgrade

$4 -> $3

AI Analysis

2026-05-05

Reason

Piper Sandler

Adam Maeder

Price Target

$4 -> $3

AI Analysis

2026-05-05

downgrade

Overweight

Reason

Piper Sandler analyst Adam Maeder lowered the firm's price target on InspireMD to $3 from $4 and keeps an Overweight rating on the shares. The firm notes the company reported good Q1 results with sales of $3.4M beating its consensus-matching estimates of $2.7M. The outperformance was driven by strength in both the U.S. and outside U.S. businesses - with Q4 marking the second full quarter of the U.S. launch. Piper is updating its model post-earnings call to reflect the temporary discontinuation of U.S. commercial activity. Altogether, the firm sees the situation as manageable and there's no change to its positive view on the company's micromesh carotid stent technology.

Lake Street

Buy

downgrade

$5 -> $4

2026-05-04

Reason

Lake Street

Price Target

$5 -> $4

2026-05-04

downgrade

Buy

Reason

Lake Street lowered the firm's price target on InspireMD to $4 from $5 and keeps a Buy rating on the shares. InspireMD's voluntary recall of the CGuard Prime 135 cm delivery system is "a disappointing setback to the U.S. launch," but the issue was identified proactively and, "most importantly," is contained to the delivery system, the analyst tells investors. The fixes required for the Prime delivery system are "both manageable and necessary to position the stent for the standard-of-care adoption it deserves," the analyst added. With the product recall InspireMD withdrew its 2026 revenue guidance of $13M-$15M, adds the analyst, who reduced the firm's 2026 revenue estimate from $13M to $8.8M.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NSPR

Unlock Now

NSPR Should I Buy

NSPR Should I Buy

Should You Buy InspireMD Inc (NSPR) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch